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DETECTION OF ANALTYES USING METAL 
NANOPARTICLE PROBES AND DYNAMIC 
LIGHT SCATTERING 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
The present application claims priority to U.S. Provisional 
Application 61/018,719 filed Jan. 3, 2008 and U.S. Provi-
sional Application 61/034,334 filed Mar. 6, 2008. Priority 
under 35 USC 119 is claimed to said provisional applications 
and the applications are incorporated by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The U.S. Govermnent may have certain rights to the inven-
tion based on National Science Foundation CAREER Award 
DMR 0552295 and DMI Award 0506531. 
FIELD OF THE INVENTION 
The present invention relates to systems and methods for 
detecting Chemical Species, Biomolecules and Biotargets 
(all termed as Analytes) using receptor functionalized metal 
nanoparticles. Receptor is a general term for any chemical 
species and biomolecules that can interact with the analytes 
through covalent or non-covalent chemical interactions. 
BACKGROUND 
There is a need to detect various Chemical Species, Bio-
molecules and Biotargets for a variety of purposes, such as 
medical diagnosis, human and animal health monitoring, life 
science research, drug screening and pharmaceutical devel-
opment, environmental protection, industrial process moni-
toring, food safety monitoring, detection of illegal drug 
usage, homeland security, monitoring of other chemical and 
biological process. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic illustration of the invention including 
three different embodiments. The illustration is an example 
based on a homogeneous immunoassay using gold nanopar-
ticles (GNP) coupled with dynamic light scattering (DLS) 
measurement. In embodiment A, two different probes are 
used. The probes are gold nanoparticles conjugated with a 
matched antibody pair. In embodiment B, a single type of 
probe is used. The analyte contains multiple binding sites 
with the probe, therefore, can cause nanoparticle aggregation 
upon binding with the receptors on the probes. In embodi-
ment C, a single type of probe is used. However, the binding 
between analytes and probes does not cause particle aggre-
gation. Instead, an aggregation inducer is present to introduce 
nanoparticle aggregation. The analyte and aggregation 
inducer compete with each other to bind with the probes. 
FIG. 2 is a basic design of a DLS system. 
FIG. 3 a-c represents schematic diagrams of DLS system 
implementing a multiple sample platform for simultaneous 
DLS measurement of multiple samples using a plurality of 
detectors (a, b) or continuous DLS measurement of multiple 
samples using a single detector and a rotatable carousel (c). 
FIG. 3(b) is a partial side view of the system shown in FIG (a). 
Note: (1) The sample platform can be movable or fixed. The 
platform shown comprises 12 fixed assay solution containers 
(in this case, 12 microwells ), or removable containers to hold 
2 
the assay solutions. (3) When it can be rotated, samples may 
be continuously added and removed from the carousel using 
removable assay solution containers as shown in (c). This 
mode can be set for continuous measurement of multiple 
5 samples at a preset time interval. ( 4) The relative angle 
between incident light beam and scattered light beam that will 
be detected by the detector is typically an angle between 0-90 
degree. Illustrated here the angle is approximately 13-25 
degree. (5) The carousel may be replaced by a microfluidic 
10 device which can be placed and removed from the carousel. 
( 6) The number of sample holders and detectors can be 1 or 
any other number. 
FIG. 4 is the average scattered light intensity of a gold 
nanorod (GNR, dimension of 10 by 40 nm), 40 nm (GNP40), 
15 and 98 nm (GNP98) spherical goldnanoparticles measured at 
different concentrations by DLS. 
FIG. 5 is: (a) The chemical structures and (b) TEM images 
of GNP and GNRparticles. (c) The UV-Vis absorption spec-
tra of GNP, GNR probes and their conjugates with an anti-
20 body pair: GNP-dAb and GNR-cAb. The two antibodies are 
anti-free PSA antibodies. (d) The size distribution measured 
from DLS ofunconjugated GNP, GNR, and (e) their conju-
gates with antibody pairs. 
FIG. 6 shows DLS data in particle size distribution of an 
25 assay solution with 1.0 ng/mL of f-PSA in sample solution 
(a). The assay results off-PSA standard solutions (b) obtained 
from DLS analysis. The assay results are expressed as the 
numerical ratio of area A versus area B as shown in (a). 
FIG. 7. (a) The chemical structures of PAA-GNP (top) and 
30 PEG-GNP (bottom). The UV-Vis absorption spectra of cit-
rate-GNP (b ), PAA-GNP ( c) and PEG-GNP ( d) at PBS buffer 
solutions (pH 7.4) with different concentrations of NaCl (leg-
ends are NaCl concentrations) 
FIG. 8. shows: (a) DLS data (particle size distribution) of 
35 the assay solution with 0 and0.1 ng/mL f-PSAin solution. (b) 
The plots of hydrodynamic diameters of nanoparticles versus 
f-PSA concentration. Two sets of assays were conducted. The 
assay showed both good intra-assay and inter-assay reproduc-
ibility. Results were obtained from the Cool Batch40 DLS 
40 system from Precision Detectors, Inc. 
FIG. 9 shows assay results for total PSA in standard solu-
tions using 100 nm GNP antibody conjugate probes. The 100 
nm GNP probes were prepared by non-covalently adsorbing 
a matched monoclonal anti-total PSA antibody pairs to two 
45 batches of gold nanoparticles. The assay results were 
expressed as average particle size diameter of the assay solu-
tion. The assays were done in two different concentration 
ranges: (a) 0.2-10 ng/mL and (b) 0.001to1 ng/mL. 
FIG. 10 shows assay results in duplicate for total PSA 
50 secreted by PC3 cells in the supernatants using 100 nm GNP 
antibody conjugate probes. The results were expressed in 
average particle size. The 100 nm GNP probes were prepared 
by non-covalently adsorbing a matched monoclonal anti-total 
PSA antibody pairs to two batches of gold nanoparticles. The 
55 cell supematants were collected after 24 hours of growth. 
Samples PC3Al, PC3Bl, and PC3Cl had approximately 1 
million, SOOK and 250K cells in the culture dish. To conduct 
the assay, 2 µL of cell supernatant was added to 40 µL of 
mixed nanoprobe solution. After incubating the solution at 
60 room temperature for 5-10 min, results were read by DLS. 
FIG. 11 is the assay results of four human serum samples 
using the same probes as described in FIG. 7 and FIG. 8. 
FIG. 12 is the assay results of four sample solutions that 
contain actin at a concentration of 34.5, 17 .3, 8.6, and 4.3 
65 ng/mL of actin, respectively. The actin solutions were cell 
lysates. The two probes were prepared by conjugating a 
matched monoclonal anti-actin antibody to two batches of 
US 8,883,094 B2 
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100 run GNPs. The first two columns (blue and dark red) are 
DLS data in average particle size from two different assays 
and the third column (light yellow) is the average of the two 
assay results. 
4 
mers or other chemical species). A sample solution suspected 
of including at least one analyte is contacted with the probes 
to form an assay solution, wherein in a presence of the analyte 
FIG. 13 shows the hydrodynamic diameter (Dh) change of 5 
assay solutions of mouse IgG mixed with two different gold 
nanoparticle probes after incubating at 37° C. for 2 hours. 
(-0-: a control made of mouse IgG with 0.1 nM BSA conju-
gated GNPs; -fl-: mouse IgG mixed with a 0.1 nM goat-anti 
mouse conjugated GNPs. The assay using BSA conjugated 10 
GNP as a control for the study) 
a portion of the probes in the analyte comprising solution 
become aggregated. Dynamic light scattering (DLS) is used 
to quantify the analyte by measuring the degree of aggrega-
tion of the assay solution. At least a presence of, and generally 
also the concentration of, the analyte in the sample solution is 
determined from DLS data obtained from the assay solution 
as determined by DLS. The concentration of the analyte 
determined can be used to base a medical diagnosis or prompt 
FIG. 14 is the results of a direct assay for mouse IgG 
detection using 0.01 nM goat anti-mouse IgG conjugated 
GNPs (GNP-anti-IgG). Measured data was fitted into a logis-
further tests to base a diagnosis, such as whether an individual 
has (or is likely to have) cancer, or other purposes such as 
envirorunental monitoring. 
tic model using a four parameter Logistic fitting without 15 
weighting. (LLOD=0.0078 ng/mL, 3a, R=2; y=187.55435+ 
(35.46758-187.55435)/(1+x/46.97037)06302 , R2 =0.9994; 
error bar: standard deviation. 
In another embodiment (the embodiment B as illustrated in 
FIG. 1 ), referred to herein as a single pro be type embodiment, 
a first probe is the only probe type provided. This probe 
contains multiple copies of a single type or mixed types of 
receptors on one nanoparticle. In this embodiment the analyte FIG. 15 is the results of a competitive assay for mouse IgG 
detection using two nanoparticle probes, GNP-IgG and GNP-
anti-IgG. Here GNP-anti-IgG serves as the probe, and GNP-
IgG serves as an aggregation inducer. Analyte mouse IgG 
competes with GNP-IgG to bind with GNP-anti-IgG. The 
concentration of both GNP-anti-IgG and GNP-IgG probes 
was 0.1 nM. Each assay solution was incubated at room 
temperature for 4.5 hours. Measured data was fitted into a 
logistic model using a four parameter Logistic fitting without 
weighting. (LLOD=283.0036ng/mL, 3a, R=2; y=42.21247+ 
(71.12096-42.21247)/(1 +x/5023.40461)076428, R2 =0.9895, 
error bar: standard deviation 
FIG. 16 is a schematic illustration ofa homogeneous detec-
tion of DNA using gold nanoparticle probes and dynamic 
light scattering. FIG. 16 discloses SEQ ID NOS 1-3, respec-
tively, in order of appearance. 
FIG. 17 is the UV-Vis absorption spectra (a) and size dis-
tribution (b) of gold nanoparticles (AuNPs) before and after 
DNA conjugation. 
FIG.18 is the size and size distribution (in diameter, run) of 
DNA-AuNP assay solutions in the presence of perfectly 
matched target DNAs (a), and single base pair-mismatched 
DNAs at a concentration of 10 µM (b ). 
FIG. 19 is the average diameters of the assay solution 
containing different concentrations of target DNAs as deter-
mined from DLS measurements and plotted against the target 
DNA concentrations. 
DETAILED DESCRIPTION 
Embodiments of the invention pertain to a highly sensitive, 
fast and convenient homogeneous one-step analytical assay 
for monitoring and detecting Chemical Species, Biomol-
ecules and Biotargets (all termed as analytes) including but 
not limited to, proteins, antibodies, antigens, enzymes, 
nucleic acids, hormones, drugs, drug intermediates, environ-
mental polluting chemicals and species, chemical and bio-
logical warfare agents, bacteria and viruses, synthetic chemi-
cal substances. 
20 can have multiple binding sites and the same probe type can 
bind to the multiple sites of the analyte to create nanoprobe 
aggregates. By way of example only, the nanoparticles may 
be conjugated with a layer of multiple polyclonal antibody 
which can bind with different epitopes of an antigen. Such 
25 binding will cause probe aggregation which is detectable by 
DLS. Another example is a nanoparticle probe with a layer of 
metal ion-binding ligands attached to the surface. The probe 
can form a coordination complex with the metal ion through 
ligands attached to the probe. When the probe is contacted 
30 with a sample that contains the metal ion as analyte, nanopar-
ticle probe aggregation will occur due to complex formation, 
which can be detected by DLS. 
In another embodiment (the embodiment A as illustrated in 
FIG. 1), referred to herein as the multiple probe type embodi-
35 ment, the method includes both a plurality of first probes and 
a plurality of second probes, wherein the second probes com-
prise a metal nanoparticle conjugated with a second receptor 
that is different from the first receptor. The first and second 
metal nanoparticles can be the same or different. In this 
40 embodiment the first and second receptor can both be selected 
to bind with the analyte and generally recognize separate sites 
on the analyte to bind. In this way, the respective receptors do 
not generally inhibit the other receptor's binding. 
In the case of receptors comprising antibodies regarding an 
45 antigen target, the antibody combination should be qualified 
as "matched pairs", meaning that they can recognize separate 
epitopes on the antigen so they do not significantly hinder 
each other's binding. In this particular case, the first and 
second receptors may be referred to herein as in ELISA as the 
50 "capture antibody" and the "detection antibody". However, 
the present invention has little relation to ELISA. ELISA is a 
heterogeneous multiple step immunoassay. Embodiments of 
the present invention provide a homogenous assay that 
removes the ELISA need for binding the capture antibody to 
55 a solid phase typically attached to the bottom of a plate well, 
adding antigen and allowing complexation with the bound 
antibody, washing to obtain unbound product, and a second 
binding step where the detection antibody is allowed to bind 
to the antigen. Another difference is the use of Dynamic light 
In a general embodiment, the invention pertains to an ana-
lytical method for the detection of analytes comprises the 
steps of providing a plurality of probes each comprising a 
metal nanoparticle conjugated with multiple copies of the 
same or different receptors. FIG. 1 is a general illustration of 
the invention. The illustration is an example based on a homo-
geneous immunoassay using gold nanoparticles (GNP) 
coupled with dynamic light scattering (DLS) measurement. 65 
The receptor can be a natural receptor (e.g. antibody, protein, 
DNA, etc.) or a synthetic receptor (e.g. molecules, ions, poly-
60 scattering (DLS) to quantify the analyte, as compared to 
ELISA which achieves quantitation by measuring the amount 
of labeled second antibody bound to the matrix through the 
use of an enzymatic probes, fluorescent probes, or radioactive 
probes. 
In a third embodiment (the embodiment C as illustrated in 
FIG. 1), the method involves the use of plurality of a single 
probe with multiple copies of receptors conjugated to the 
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nanoparticle surface. The probe will mainly bind to one site of 
the analyte. The probe particles can form aggregates by a 
molecule or material different from the analyte. This mol-
ecule or material can be called as "aggregation inducer". This 
molecule or material can be another chemical species, a dif-
ferent nanoparticle, or a material that is co-existed with ana-
lyte in the sample solution, or that is added to the sample 
solution from sources other than the sample solution. The 
aggregation inducer competes with analyte to bind with the 
probe. The binding between probes and analyte will inhibit 
the probe aggregation caused by aggregation inducer. When 
the probes are contacted with the sample solution, the probes 
will form aggregate introduced by the aggregation inducer 
molecule. The analyte will not cause or cause much less 
aggregation of nanoparticle probes than the aggregation 
inducers. Therefore, ifthere is analyte in the sample solution, 
there will be less degree of probe aggregation. The degree of 
probe aggregation is inversely proportional to the analyte 
concentration. An example for this embodiment is a competi-
tive immunoassay that utilizes a probe containing a single 
type of primary antibody on the nanoparticle surface. This 
probe may be aggregated together by mixing with a second-
ary antibody solution. In this case, the secondary anti body is 
the aggregation inducer. For example, ifthe probe contains a 
primary antibody raised from mouse, a goat anti-mouse IgG 
may be used as an aggregation inducer. When the probe 
solution is mixed with sample solution that contains the anti-
gen, the antigen molecule will compete with the secondary 
antibody to bind with the probe. Because the antigen-probe 
binding will not cause probe aggregation. As a result, when 
antigen is present in the sample, less degree of probe aggre-
gation will occur compared to when antigen is absent from the 
sample. The antigen concentration in the sample solution can 
be quantified by DLS measurement and is inversely propor-
tional to the degree of nanoparticle aggregation. 
Quantitation according to embodiments of the present 
invention comprises directing light (e.g. ultraviolet, visible, 
near infrared or infrared) toward the analyte comprising solu-
tion mixed with plurality of nanoparticle probes, and measur-
ing a scattered light signal from the assay solution. At least a 
presence of, and generally also the concentration of, the ana-
lyte in the sample solution is determined from using dynamic 
light scattering to obtain DLS data from the assay solution. 
DLS data includes but is not limited to particle size, and/or 
particle size distribution and/or diffusion coefficient of par-
ticles in the assay solution. The concentration of the analyte 
determined can be used for multiple purposes as described 
herein, e.g., to base a medical diagnosis or prompt further 
tests to base a diagnosis, such as whether an individual has (or 
is likely to have) cancer. 
The nanoparticles are generally metals, such as gold or 
silver which are both known to provide large scattering cross 
sections (Yguerabide, J.; Yguerabide, E. E. Anal. Biochem. 
1998, 262, 137). The nanoparticles can have different shapes 
and chemical compositions such as spherical nanoparticles, 
nanorods, nanoshells, alloyed nanoparticles (nanoparticles 
with more than one metal components), nanocages, nanorice, 
etc. Other nanoparticles or colloidal particles that provide 
large scattering cross sections may be useful as well. The 
present invention is generally described herein with respect to 
gold nanoparticles. For example, gold nanoparticles, includ-
ing spherical particles, nanorods or nanoshells with a size 
ranging from 10 s to 100 s nanometers, provide exceptionally 
large light scattering cross sections in the surface plasmon 
resonance wavelength region. The magnitude oflight scatter-
ing by a gold nanoparticle is orders of magnitude higher than 
light emission from strongly fluorescing dyes such as fluo-
6 
rescein. This strong light scattering property of gold nanopar-
ticles has been applied to optical microscopic imaging of 
biological cells for qualitative evaluation, but not for quanti-
tative analysis and assays in homogeneous solutions by 
dynamic light scattering method. The strong light scattering 
makes gold and silver nanoparticles as excellent optical 
probe/tracer for analytical applications. 
Receptors can be any moiety known to associate to a given 
target analyte. In competitive assay embodiment, receptor 
10 will also bind to the aggregation inducers. Analytes and 
aggregation inducers compete to bind with the receptor. 
The receptors are adapted for binding to an analyte. Recep-
tors can include, but are not limited to, antibody, DNAs, 
RNAs, proteins including enzymes, cells or cell components, 
15 biomimetics, synthetic molecules or materials which can spe-
cifically bind to the analyte. Biomimetic receptors can 
include molecular imprint antibodies, DNA-based aptamers, 
and peptide nucleic acids (PNA). 
The receptor molecules (natural and synthetic) will be 
20 attached to the metal nanoparticles through covalent or non-
covalent chemical interactions to prepare the probe. Methods 
for attachment ofbioreceptor molecules such as antibody to 
gold nanoparticles through non-covalent chemical interac-
tions have been well known and commonly practiced. For 
25 covalent attachment, the nanoparticles should have at least 
one chemical functional group such as carboxylic acid or 
amine on the particle surface, or any other suitable functional 
groups that can link the receptors to the nanoparticles. The 
receptor molecules will react with the chemical functional 
30 group to form a covalent chemical bonding. 
Analytes can be any chemical species, biomolecules and 
biotargets. Chemical species are any natural and synthetic 
chemical substances (neutral or charged, with or without a 
confirmed molecular structure), ions such as mercury (II), 
35 lead (II), polymers, materials, drugs and pharmaceuticals, 
drug candidates, or any other chemical substances. Biomol-
ecules are generally biochemical substances, such as pro-
teins, enzymes, antibodies, antigens, haptens, drugs, drug 
intermediates or fragments, hormones, polysaccharides, 
40 metabolites, nucleic acids. Biotargets are biological species 
or living systems, such as bacteria, virus or related compo-
nents. The sample that is to be assayed using the invention 
described can be biological or non-biological based. The 
biological sample can be, but is not limited to, human and 
45 other animal blood, plasma, serum, urine, saliva, sputum, or 
other bodily fluids; cell supernatants, cell media, or cell 
lysate; tissue extracts. The non-biological samples can be, but 
are not limited to, water from different resources, liquid 
extracts from different materials and objects, etc. The sample 
50 solution may or may not need to be pre-processed chemically 
or physically before conducting the assay. The processing is 
to eliminate large particles or other factors that may interfere 
significantly with the assay results. Examples of physical 
processing include filtration, centrifuge, ultrasonication, pre-
55 cipitation, heating or cooling etc. Examples of chemical pro-
cessing include adding a chemical or chemicals such as 
sample diluents, surfactants, oxidation or reduction reagents, 
disinfectants, cell lysing reagents, denaturing and de-hybrid-
ization agents to pre-treat the samples. The amount of the 
60 sample used for the assay can vary from nano liters to micro-
liters. A portion of the sample solution may be divided into 
multiple smaller portions of samples using a liquid handling 
system or micro or nanofluidic device for multiple analysis. 
DLS is a technique used widely for particle size and size 
65 distribution studies (Berne, B. J.; Pecora, R. Dynamic light 
scattering: with applications to chemistry, biology, and phys-
ics; 1976, by Wiley: New York.) The principal of DLS has 
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been established more than three decades ago and a wide 
range of DLS instruments and systems are commercially 
available. This technique is based on the Brownian motion of 
spherical particles which causes a Doppler shift of incident 
laser light. The diffusion coefficient of particles are measured 
and the size of the particles is calculated according to the 
Stokes-Einstein relation. Although studies have been 
reported on bioconjugation of metal (e.g. gold) nanoparticles 
and biomolecular interaction-directed nanoparticle aggrega-
tion, prior to the present invention, DLS has not been dis- 10 
closed in conjunction with metal (e.g. gold) nanoparticle 
probes for homogeneous and quantitative assays. Applied to 
the embodiments of the present invention, DLS can detect 
particle size change, or size distribution change caused by the 
formation of nanoparticle dimers, trimers, oligomers, and 15 
aggregates. This capability makes DLS a suitable analytical 
tool for a quantitative assay according to embodiments of the 
invention. 
Metal nanoparticles used in the invention can be monodis-
persed or poly-dispersed in terms of size. "Poly-dispersed" 20 
means the nanoparticle solution contains nanoparticle with 
different size ranges, while "monodispersed" means all nano-
particles have the same or similar sizes. The metal nanopar-
ticles used in the invention generally have an average size in 
diameter in the range of 1-1000 nm. The nanoparticles gen- 25 
erally have a layer of molecules, ions, or polymers attached 
covalently or non-covalently on the particle surface to prevent 
nanoparticle from de-stabilization. These molecules, ions and 
polymer may or may not have thiol groups or amine groups in 
them. Thiol and amine groups have high affinity towards gold 30 
nanoparticles. Other molecules with high affinity for gold and 
silver nanoparticles may be used. Citrate is a common ligand 
used to protect and stabilize gold and silver nanoparticles. 
The citrate molecules bind with gold and silver nanoparticles 
through electrostatic interactions. The preparation of gold 35 
nanoparticles or colloids stabilized by citrate molecules was 
established more than 5 decades ago and has been used since 
then (Turkevitch, J.; Stevenson, P. C.; Hiller, J. Discuss. Fara-
day Soc. 1951, 11, 55; and Frenz, G. Nature Phys. Sci. 1973, 
241, 20.) Polymers or smaller oligomers such as oligo(ethyl- 40 
ene oxide) (OEG) or poly( ethylene oxide) (PEG) with one or 
multiple thiol groups on the polymers are also used to modify 
gold and silver nanoparticle surface. OEG or PEG-protected 
gold nanoparticles are much more stable than citrate-stabi-
lized nanoparticles in high salt content solutions such as 45 
human blood and other biological fluids. The typical salt 
concentration of these biological fluids is about 100-200 mM. 
8 
embodiments of the invention may also use silver nanopar-
ticles or other types of nanoparticles that provide large scat-
tering cross section and are detectable at very low concentra-
tion using DLS technique. Moreover, the invention is not 
limited to the detection of chemicals and biological mol-
ecules in biological samples. It may also be used for detection 
of chemical substances in non-biological samples. 
EXAMPLES 
The Examples provided below are all non-limiting 
examples. Specific materials disclosed are only exemplary 
materials. For example, the metal nanoparticles are not 
restricted to gold nanoparticles (GNP), the analytes are not 
limited to biomolecules. 
Example 1 
A One-Step Homogeneous Immunoassay for Cancer 
Biomarker Protein Detection 
Millions of people around the world face the risk of cancer, 
which have been one of the leading causes of mortality. An 
early detection of cancer can significantly improve the treat-
ment and survival rate of cancer patients. As tumor develops, 
the cells, tissues and organs can release, increase or decrease 
the release of certain chemicals in the circulating blood sys-
tem. These specific chemicals are called biomarkers. Biom-
arkers detection and monitoring has tremendous significance 
for cancer diagnosis and treatment. 
An ideal immunoassay technique for biomarker detection 
is expected to meet the following 4-S criteria: simple, highly 
sensitive, highly specific, and requires small volume of 
samples. Despite the existence of numerous assay and sensor 
technologies, an ideal bioanalytical tool that meets all these 
criteria has yet to be developed. Most bioassay techniques or 
biosensors either lack the high sensitivity, involve large vol-
ume of samples, and/or complicated assay procedures/data 
analysis that can only be done by trained professionals. A 
typical heterogeneous sandwich-type immunoassay such as 
ELISA, chemiluminescence immunoassay, involves the anti-
body immobilization, multiple steps of incubation and wash-
ing cycles, followed by signal amplification and reading. 
From the initial antibody immobilization to the final reading 
of the assay results, the entire immunoassay can usually take 
hours to days to complete. A traditional immunoassay is 
rather time-consuming and labor-intensive. Although in 
medical testing labs, these assays are all done by fully auto-
mated instruments, such instruments are bulky, expensive to 
manufacture and to maintain due to complicated assay pro-
cedures. Such systems are not suitable for point-of-care pur-
poses and for individual research labs. Also, a typical plate 
immunoassay requires relatively large volume of samples ( 50 
to 100 s µL), therefore, is not suitable for a single drop of 
A new metal particle is also described herein. This metal 
particle has a layerof poly( acrylic acid) (PAA) attached to the 
particle surface. The PAA are attached to nanoparticles 50 
through non-covalent interactions such as electrostatic, van 
der Waals interactions and hydrogen bonding. Similar to 
OEG and PEG-protected nanoparticles, PAA-protected 
nanoparticles are also much more stable in high salt content 
solutions. 55 blood analysis. Protein microarrays have been developed to 
minimize the amount of samples needed for the assay, with 
another distinctive advantage of multiplexing capability. 
However, protein microarrays involve the use of sophisticated 
software for data analysis, and the cost for assay development 
New methods are also described regarding how to extract 
an analyte (e.g. antigen) concentration from DLS analysis. 
The method described obtaining quantitative data from DLS 
measurements. 
The present invention is not limited to the disclosure above 
or examples provided below. The invention can be used for 
other applications, for example, embodiments of the inven-
tion can generally be used for the detection of any chemical, 
biological molecule or substance that can cause nanoparticle 
aggregation or deaggregation after metal (e.g. gold) nanopar-
ticles are modified with appropriate receptors towards these 
species. As noted above, other than gold nanoparticles, 
60 and validation is prohibitively too high for routine purpose 
and for most research labs to adopt for biomarker research. 
As illustratedinFIG.1, embodimentA, goldnanoparticles 
(GNP) in the size range of about 1-1000 nm with a large light 
scattering cross section, are used as an optical probe to couple 
65 with an antibody pair (capture and detector antibody, cAb and 
dAb) for a specific cancer biomarker. These two nanoparticle 
probes (GNP-cAb and GNP-dAb) are then mixed with a 
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sample solution, which may or may not need to be pre-filtered 
or chemically treated to remove large particles. In the pres-
ence of antigen, the antigen-antibody binding will lead to 
nanoparticle aggregation. The formation of nanoparticle 
aggregates versus individual nanoparticle probes can be 
quantified by DLS, and this quantitative information can be 
correlated to the antigen concentration. Alternatively, if the 
distribution peaks of individual particles and particle aggre-
gates are not separated, then the average particle size (for 
example, it can be expressed as hydrodynamic diameter) 
increase due to aggregate formation will be used to correlate 
with the antigen concentration. 
Gold nanoparticles, including spherical particles, nano-
rods and nanoshells with a size ranging from 10 s to 100 s 
nanometers, are known to have a large light absorption and 
scattering cross section in the surface plasmon resonance 
(SPR) wavelength region. In normalized terms, the scattering 
cross section of a 30 nm gold particle at its SPR region is 
about 250 times larger than a 30 nm polystyrene particle. As 
compared to fluorophores, the scattering light intensity from 
a 60 nm gold nanoparticle is four to five orders of magnitude 
higher than a strongly fluorescent fluorescein molecule 
(Y guerabide, J .; Y guerabide, E. E. Anal. Biochem. 1998, 262, 
137). 
Dynamic light scattering (DLS), also known as photon 
correlation spectroscopy or quasi elastic light scattering, is a 
technique used widely for particle size and size distribution 
analysis. This technique is based on the Brownian motion of 
spherical particles which causes a Doppler shift of incident 
laser light. The diffusion coefficients of particles are mea-
sured and the size of the particles is calculated according to 
the Stokes-Einstein relation. Although a very limited number 
of studies have been reported more than three decades ago to 
use DLS for quantitative and homogeneous immunoassay, in 
these previous works, polymer latex particles were used as 
light scattering enhancer to conjugate with antibody as the 
optical probe (Cohen, R. J.; Benedek, G. B. Immunochemis-
10 
as very attractive light scattering probes for immunoassays 
according to embodiments of the invention. 
Based on the principal as outlined in FIG. 1, the inventors 
developed an immunoassay using the invention to detect free 
prostate specific antigen (free PSA), a biomarker protein 
associated with prostate cancer. Prostate specific antigen 
(PSA) is an FDA-approved biomarker for prostate cancer 
diagnosis. The total PSA concentration of a healthy male is in 
the range of a few ng/mL and the free PSA (f-PSA) concen-
10 tration is typically less than 1 ng/mL, in the range of 10-25% 
of the total PSA. Free PSA is the unbound form of prostate 
specific antigen. Studies have shown that the percentage of 
f-PSA in total PSA is lower in patients with prostate cancer 
than those with benign prostate hyperplasia. The free PSA 
15 level is now being introduced and studied as an additional 
biomarker for prostate cancer screening and diagnosis. 
In this study, the inventors prepared two types of gold 
nanoparticles: one is a citrate-stabilized spherical gold nano-
particle (Ct-GNP, diameter 37 nm), and another one is a 
20 cetyltrimethyl ammonium bromide (CTAB)-protected gold 
nanorod (CTAB-GNR, 10 by 40 nm) (FIG. Sa). The two 
antibodies were conjugated to the two nanoparticles by non-
covalent adsorption. This process is known and familiar to 
those who are skilled in this field. A TEM image and UV-Vis 
25 absorption spectra of GNP and GNR are shown in FIG. Sb and 
c. The particle size and size distribution was analyzed by DLS 
(FIG. Sd). The successful conjugation of nanoparticles with 
detector antibody and nanorods with capture antibody was 
first confirmed by UV-Vis spectral analysis and DLS mea-
30 surement (FIG. Sc and e). Compared to the original GNPs and 
GNRs, the SPR absorption band of the nanoparticles were 
shifted slightly due to the surface chemistry change of the 
conjugated particles. The size of the conjugatednanoparticles 
also increased from 3 7 to 57 nm and 30 to 37 nm, respectively, 
35 for the GNPs and GNRs. These data suggest that the two 
antibody were successfully conjugated to GNP and GNRs 
respectively. It is estimated that the number of antibody 
attached to the nanoparticle surface is between 10-100 per 
particle. Larger particle size will lead to attachment of more try 1975, 12, 963-966. Von Schulthess, G. K.; Cohen, R. J.; 
Benedek, G. B. Immunochemistry 1976, 13, 963-966). Com-
pared to gold nanoparticles at similar sizes, the scattering of 
polymer latex particles is much weaker. This low scattering 
intensity is not sufficient to suppress the scattering signal 
from other particles in the sample solution, making this light 
scattering immunoassay technique unsuitable or significantly 
limited for detection of low abundance protein analytes. By 
using gold nanoparticles as the probe, the scattered light 
intensity from gold nanoparticle probes is sufficiently strong 
enough to suppress the background light scattering arising 
from the sample solution, therefore, providing much 50 
enhanced sensitivity to the immunoassay. 
40 antibodies to the particle surface. 
The homogenous immunoassay of f-PSA was then con-
ducted in solution using the conjugated nanoparticles and 
nanorods. The two nanoprobes were mixed in 1:2.5 (GNP-
dAb:GNR-cAb) ratio and then added to the standard f-PSA 
45 solutions with different concentrations. The GNR probe was 
added in excess and used as an internal reference. The assay 
solution was incubated at room temperature for 30 min before 
DLS analysis. DLS analysis was conducted on a Cool 
Batch40 system from Precision Detector, Inc. 
FIG. 6a is a typical size distribution of mixed nanoprobe 
solution in the presence of 1 ng/mL of f-PSA. For the pure 
nanoparticle and nanorod conjugates, only one size distribu-
tion of particles was observed from the distribution, as seen 
from FIG. Se. With f-PSA added to the nanoprobe solution, 
The inventors first developed a homogeneous one-step 
immunoassay for prostate cancer biomarker detection using 
the embodiment A as illustrated in FIG. 1 (Huo, Q. et al. J. 
Am. Chem. Soc. 2008, 130, 2780-2782). In this work, a 
spherical gold nanoparticle with a diameter of 40 nm and a 
gold nanorod with a dimension of 10 by 40 nm were used to 
prepare the matched antibody conjugate probes. In a feasibil-
ity study, the inventors analyzed the detection limit of gold 
nanoparticles and nanorods using DLS. FIG. 4 shows the 
average scattered light intensity of a gold nanorod (GNR, 
dimension of 10 by 40 nm), 37 nm (GNP37), and 98 nm 
(GNP98) spherical gold nanoparticles measured at different 
concentrations by DLS. From this data, the detection limit of 
three gold nanoparticle materials: GNR, GNP37, and 
GNP98, was determined to be 0.4 µM, 0.02 µMand 0.7 fM, 
respectively. This high sensitivity makes gold nanoparticles 
55 DLS measurement detected two groups of particle sizes (FIG. 
6a, peak area A and B), one is centered at below 60 nm 
representing individual nanoparticles and nanorods (area B), 
and one above 100 nm corresponding to nanoparticle-nano-
rod oligomers (area A). The relative ratio (here we used the 
60 scattered light intensity ratio) of nanoparticle oligomers in the 
size range of 60-500 nm (area A) versus individual nanopar-
ticles in the size range of 20-60 nm range (area B) can be 
numerically calculated from the size distribution curve. FIG. 
6b is the plot of this numerical ratio versus f-PSA concentra-
65 tion. With increased concentration off-PSA, the relative per-
centage of nanoparticle oligomers increased while the per-
centage of individual nanoprobes decreased. Using the same 
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nanoprobes in buffer solution, we conducted the analysis of 
an unknown sample solution (f-PSA concentration at 0.5 
ng/mL ). The determined concentration corresponds very well 
to the true concentration of the sample (FIG. 6b, data indi-
cated with a red asterisk). 
The immunoassay demonstrated by the inventors offers 
several incomparable advantages over traditional immunoas-
say and other state-of-the-art bioanalytical techniques: (1) an 
extremely simple assay process; (2) requires minute amount 
of samples (0.1 to several µL) for the assay, which means we 
can detect multiple biomarkers from a single drop of blood 
sample taken from a fingertip; (3) high sensitivity (fM to aM 
in concentration, or fg in absolute mass) without any ampli-
fication steps; (4) low cost with high throughput analysis 
capability; (5) extremely fast analysis time (a complete assay 
can be done in less than 5 minutes). 
Example 2 
Improved Homogeneous Immunoassay Using New 
Robust Gold Nanoparticle Probes 
Development of robust gold nanoparticle probes: Two new 
nanoparticle probes with improved stability in high ionic 
strength buffer solutions than citrate-stabilized gold nanopar-
ticles were developed. One is a spherical gold nanoparticle 
stabilized by poly( acrylic acid) (PAA) and another one is a 
thiolated poly( ethylene glycol) ligand (PEG)-stabilized gold 
nanoparticle (FIG. 7a). Both nanoparticles were obtained 
from the surface modification of citrate-stabilized gold nano-
particles. The PEG-protected GNPs were synthesized 
according to the following procedure: Citrate-protected 
GNPs with an average core diameter of30-35 nm were first 
synthesized according to a reported method (Turkevitch, J.; 
Stevenson, P. C.; Hiller, J. Discuss. Faraday Soc. 1951, 11, 
55; and Frenz, G.NaturePhys. Sci. 1973, 241, 20). Then 1 mL 
aqueous solution of a thiolated and bifunctional PEG ligand 
as shown in FIG. 7, HS-PEG-COOH (MW of PEG: 3000, 
from Rapp Polymers) (2xl0-4 M) was added drop wise into 
10 mL of citrate-protected GNPs solution. The mixture was 
allowed to shake at room temperature overnight. The HS-
PEG-COOH ligand functionalized GNPs were purified by 
centrifuge and washed with deionized water three times. The 
PEG-GNPs were suspended in pure de-ionized water for 
further use. 
12 
nificant aggregation, while citrate-stabilized gold nanopar-
ticles aggregate severely at a salt concentration of 30 mM. 
The PEG-protected GNPs can exist in a buffer solution with 
a NaCl concentration of 100 mM without significant aggre-
5 gation. The significantly increased stability of PAA and PEG-
protected gold nanoparticles was further confirmed by size 
analysis using DLS (data not shown here). The physiological 
salt concentration of human blood is in the range of 100-150 
mM. Both PAA and PEG-protected gold nanoparticles syn-
10 thesized in our study can be suitable as a nanoprobe for future 
assay of biological samples. 
Both PAA and PEG-protected GNPs were used to conju-
gate with anti-f-PSA antibody pairs and an immunoassay of 
f-PSA conducted. Very similar immunoassay results were 
15 obtained from both nanoparticle conjugates, but only data 
from PEG-GNPs are presented here as an illustration. The 
conjugation of antibody pairs for PAA-GNPs was done 
through a simple non-covalent adsorption, similar to conju-
gating antibody to citrate-protected GNPs. The conjugation 
20 of antibody pairs to PEG-GNPs was done by covalent chem-
istry through amide bond linkage. After conjugation, the aver-
age diameter of the nanoparticles increased in average by 
10-15 nm, corresponding to the expected size increase from 
PEG-GNPs or PAA-GNPs covered with a layer of antibody. 
25 Immunoassay of f-PSA in standard solution was then con-
ducted using these nanoparticle probes. For this assay, PEG-
GNPs conjugated with capture and detector anti-f-PSA anti-
body were mixed in equal amount and the average 
nanoparticle size increase caused by nanoparticle aggrega-
30 tion was monitored and analyzed by DLS. FIG. Sa is the size 
distribution of nanoparticles in the assay solution with 0 
ng/mL and 0.1 ng/mL f-PSA present, and FIG. Sb pertain to 
the assay results from two different experiments. From FIG. 
Sa, one can see that when analyte f-PSA is present, the aver-
35 age particle size of the assay solution is increased compare to 
assay solution that has no analyte f-PSA in the sample solu-
tion (compare the two dark grey-colored distribution peaks, 
the white-colored particle distribution peaks are from impu-
rities). The average particle size (here expressed as the hydro-
40 dynamic diameter) increases proportionally with increased 
analyte concentration, as seen from FIG. Sb. The assay of 
each sample solution was conducted in duplicates. The stan-
dard deviation of each concentration tested is very small, 
indicating excellent intra-assay reproducibility, while the 
45 inter-assay reproducibility is also very good. 
The PAA-protected GNPs were synthesized according to 
the following procedure: 1.5 mL of sodium citrate solution 
(38.8 mM) was added quickly into a boiling aqueous solution 
ofHAuC14 (0.35 mM, 100 mL) under vigorous stirring. After 
boiling for 15 min, 2 mL of PAA aqueous solution (27 50 
mg/mL, pH: -3) was added drop wise to the above solution. 
The mixture was allowed to continue boiling for 4 hours. 
After the solution was cooled to room temperature, the nano-
particle product was concentrated by centrifuge, washed thor-
oughly with deionized water twice, followed by washing with 55 
a diluted NaOH solution (pH: 10) twice. The PAA-modified 
GNPs were then redispersed in deionized (DI) water for fur-
ther use 
The following seven biomarkers are currently being tested 
as target analytes for the immunoassay development: free-
PSA, total PSA, CA 125, CA 15.3, CA 19-9, Her-2/neu and 
CEA. These biomarkers are associated with one or more of 
the following cancers: prostate, breast, ovarian, pancreatic, 
liver, lung and colorectal cancer. Other than CEA, all other 
biomarkers are FDA-approved serum biomarkers. The 
method described herein can be essentially applied to any 
biomarker. Thus, the bioassay technique described herein is 
not limited to these particular cancer biomarkers. It may also 
be extended to the analysis of other proteins, antibodies, 
antigens, DNAs, RNAs, as well as other biological targets. 
A stability comparison study was undertaken on citrate-
stabilized, PAA and PEG-stabilized gold nanoparticles in 60 
buffer solutions with different salt concentrations using UV-
Vis absorption spectroscopy (FIG. 7b, c and d, respectively). 
When gold nanoparticles start to aggregate, the surface plas-
mon resonance band will shift and become broadened. 
According to UV-Vis spectra as shown in FIG. 7, PAA-stabi- 65 
lized GNPs remain stable in a PBS buffer solution with a 
NaCl concentration up to 150 mM for 24 hours without sig-
Example 3 
Development of a one-step homogeneous immunoassay 
with improved sensitivity and dynamic range: As shown in 
FIG. 4, the light scattering intensity from a 100 nm GNP is 
substantially higher than a 40 nm GNP. Most recently, using 
GNPs with an average core diameter of 100 nm, we prepared 
a set of nanoparticle probes for total prostate specific antigen 
(PSA) detection. The average particle size (or so-called 
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hydrodynamic diameter of the particles) of the assay solution 
was recorded to determine the analyte concentration. The two 
matched antibody for total PSA were conjugated to citrate-
protected 100 nm GNPs to form two nanoparticle probes. 
Using this set of new probes, we were able to detect total PSA 5 
at a concentration as low as 1 pg/mL and extend the dynamic 
range of the assay to two concentration ranges: 0.1-10 and 
0.001-1 ng/mL (FIG. 9a and b, the two dynamic ranges were 
obtained by adjusting different amount of samples added to 
the nanoprobe solution: (a) 2 µL sample was added to 40 µL 10 
of probe solution; (b) 20 µL of sample was mixed with 20 µL 
of probe solution). While the high concentration range may 
14 
a standard protein solution to monitor the success of the 
Western blot. By conjugating a matched pair of monoclonal 
antibody with 100 nm GNPs, the inventors developed two 
probes for homogeneous assay of actin using dynamic light 
scattering. FIG. 12 is the assay results of a series of actin 
solutions. The results correspond well to the results obtained 
from Western blot. The concentrations of the four samples, 
actinl to actin4, are approximately 34.5, 17 .3, 8.6, and 4.3 
mg/mL respectively, for the Western blot analysis. The detec-
tion limit of actin by Western blot is roughly at 2 mg/mL. 
These four samples were diluted 1 million times to 34.5, 17 .3, 
8.6, and 4.3 ng/mL respectively, for the homogeneous immu-
noassay using the invention as described herein. As seen from 
FIG. 12, the difference between the four actin samples can be 
be used for routine screening purpose, the low concentration 
range may be used for monitoring cancer recurrence after 
prostatectomy. 15 clearly seen. The sensitivity of the homogeneous immunoas-
say disclosed in this invention is about six orders of magni-
tude higher than the traditional Western blot. The amount of 
the sample solution used in the present assay (2-5 micro liters) 
Additionally, we used this assay to detect PSA secreted 
from prostate cancer cells, PC3, in cell supernatants collected 
after 24 hours of growth. The results are shown in FIG. 10. 
Samples PC3Al, PC3Bl, and PC3Cl had approximately 1 
million, SOOK and 250K cells in the culture dish. To conduct 20 
the assay, we simply added 2 µL of cell supernatant to 40 µL 
of mixed nanoprobe solution. After incubating the solution at 
room temperature for 5-10 min, results were read by DLS in 
less than 1 min. Comparing PC3Al, PC3Bl, andPC3Cl, the 
difference in PSA level can be clearly seen (FIG. 10). The 25 
reproducibility of the assay is very good (data shown in FIG. 
10 are duplicates), and assays conducted using different 
batches of nanoprobes are also very reproducible. We used a 
commercial available total PSA ELISA kit (Anogen) to test 
these three cell supernatant samples. The kit was not able to 30 
detect PSA at all from all three samples (the validity of the 
assay kit was confirmed by assay of standard PSA solution 
included in the kit as well as a number of human serum 
samples). These results clearly demonstrated the unmatched 
superiority of the new assay described in this invention com- 35 
pared to commercial immunoassay products. 
Using the 100 nm GNP probes, the inventors also analyzed 
the relative level of total PSA from four different human 
serum samples: F6901, M7903, M4406, and M5512. The 
particle size analysis results of the assay solutions are shown 40 
in FIG. 11. "F" means the subject is a female and "M" means 
the subject is male. These human subjects are known as 
normally healthy and have not been diagnosed with prostate 
cancer. The first two digits in the sample name is the year 
when the subject was born. From the particle size analysis 45 
results, the order of total PSA level should be: 
M4406>M7903,,,M5512>>F6901. M5512 has a clinically 
determined total PSA level of0.6 ng/mL. This order of total 
PSA level reflects roughly the total PSA level difference 
between females and males, and males at different ages. 50 
Females should not have or have extremely low level of PSA, 
which PSA level increases on males whose age is over 60-65. 
Although the absolute value of total PSA level has yet to be 
determined through the establishment of an accurate calibra-
tion curve, so far these results indicate that the immunoassay 55 
as described in this invention can be used for analyte detection 
from human blood and serum samples. 
Example 4 
is also substantially smaller what needs to be used (100 s 
microliters) for Western blot analysis. 
Example 5 
A one-step competitive and non-competitive assay for 
mouse IgG detection using a goat anti-mouse IgG gold nano-
particle probe: In this example, the inventors developed two 
formats of assays for mouse IgG (immunoglobulin G) detec-
tion using the embodiments B and C as illustrated in FIG. 1. 
This study demonstrates the possibility of both competitive 
and non-competitive assay using the described invention. 
Goat anti-mouse IgG is a secondary antibody that has specific 
binding affinity towards mouse IgG, a primary antibody. The 
secondary antibody may bind to the Fab, Fab' or Fe region of 
the primary antibody, therefore, mouse IgG is considered to 
have multiple binding sites for the secondary antibody. 
In a first format of assay that we developed for mouse IgG 
detection, mouse IgG was directly mixed with goat anti-
mouse IgG conjugated GNPs (40 nm, GNP-anti-IgG). The 
conjugation of goat anti-mouse IgG to GNPs was done by 
non-covalent adsorption. Due to the multiple binding sites of 
primary mouse IgG by the secondary antibody, mouse IgG 
caused nanoparticle aggregation. FIG. 13 is an assay con-
ducted with a probeconcentrationof0.1 nM, whileFIG.14 is 
an assay conducted with a probe concentration at 0.01 nM. In 
this one-step assay, mouse IgG can be detected at concentra-
tions from 7 .8 pg/mL to 50 ng/mL (or approximately 52 fM to 
0.33 nM), when the probe concentration was set at 0.01 nM 
(results from FIG. 14). The detection limit and dynamic range 
of the assay may be adjusted using different concentration of 
the nanoparticle probe, as revealed from comparison of FIG. 
13 with FIG. 14. This example is an illustration of embodi-
ment B as described in this invention and FIG. 1, using a 
single type of probe to detect an analyte that has multiple 
binding sites to the single type of receptor attached to the 
nanoparticle probe. 
A second format of assay developed in this study is a 
competitive assay conducted by using both mouse IgG and 
goat anti-mouse IgG-conjugated GNPs, that is, GNP-IgG and 
GNP-anti-IgG. The GNP-anti-IgG serves as the probe and 
Immunoassay for actin using the one-step homogeneous 
immunoassay as described in this invention: Actin is a major 
component of both the cytoskeletal and contractile structures 
in all cell types. It varies in amount, being related to the type 
of differentiation and to the functional state of cells and 
tissues. Actin can be found in two different forms, the globu-
lar or the fibrillar state. Actin is often used in Western blot as 
60 GNP-IgG serves as an aggregate inducer to compete with 
analyte mouse IgG for binding with GNP-anti-IgG. The 
mouse IgG-conjugated GNP probes were prepared by conju-
gating biotinylated mouse IgG to a streptavidin-coated GNP. 
When simply mixing the two GNP probes together in solution 
65 in approximately 1: 1 mole ratio, the two GNP probes will 
aggregate together due to specific binding between mouse 
IgG and goat anti-mouse IgG molecules. The addition of 
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mouse IgG as a target protein in the mixed probe solution 
caused a reduction of aggregation between two nanoparticle 
probes. The mouse IgG analyte in solution will bind with the 
GNP-anti-IgG, therefore, inhibiting the binding of GNP-IgG 
with GNP-anti-IgG to form aggregates. The reduction of 
aggregation was then used to correlate with the target protein, 
mouse IgG, concentration. FIG. 15 shows the assay results 
expressed as the average particle size of the assay solution in 
hydrodynamic diameter versus the analyte concentration. An 
inverse relation is found from the average particle size versus 
analyte concentration. In this assay, mouse IgG can be 
detected at a concentration from approximately 100 to 100, 
000 ng/mL in solution. This competitive assay avoided the 
problem of "hook effect" as often encountered in non-com-
petitive assays. 
Through this study, the inventors demonstrate that gold 
nanoparticles with their strong light scattering property, can 
16 
Raman spectroscopy (Taton, T. A.; Mirkin, C. A.; Letsinger, 
R. L. Science 2000, 289, 1757. (b) Cao, Y. W.; Jin, R. C.; 
Mirkin, C. A. Science 2002, 297, 1536), have been developed 
to improve the detection limit to femtomolar and attomolar 
range. However, all these amplification methods involve 
complicated multiple-step procedures that are not only time 
consuming, but also often cause problems in reproducibility. 
In this work, the inventors applied the invention for DNA 
detection. As illustrated in FIG. 16, two sets of single stranded 
10 DNA probes are functionalized onto citrate-protected gold 
nanoparticles (DNAl-AuNP and DNA2-AuNP). When the 
two DNA-functionalizedAuNP probes are mixed in a sample 
solution that contains complementary target DNAs, the 
hybridization of target DNA with two nanoparticle probes 
15 will cause nanoparticles to form dimers, trimers, and larger 
aggregates. This nanoparticle aggregation will increase the 
average diameter of the whole nanoparticle population, 
which can be detected by DLS analysis. The average diameter 
increase of the nanoparticles can then be correlated quantita-
be used as a highly sensitive optical probe to replace tradi-
tional polymer latex particles for laser light scattering immu-
noassay development. The sensitivity and dynamic range of 
such assays can be adjusted very conveniently to the expected 
range by selecting appropriate nanoparticle probe concentra-
tions and assay conditions. A single type of probe, or more 
than one type of probes may be used for the assay. Both 
competitive and non-competitive assay formats may be con- 25 
sidered in the actual assay development for each individual 
protein analyte. 
20 tively to the target DNA concentration. A higher target DNA 
concentration should lead to more extensive nanoparticle 
aggregation, and larger average nanoparticle size increase as 
shown in FIG. 16. 
In this work, the inventors synthesized a citrate-stabilized 
gold nanoparticle with a core diameter of30 nm according to 
a reported procedure (Turkevich, J.; Stevenson, P. C.; Hillier, 
J. Discuss. Faraday Soc. 1951, 11, 55). Two DNA probes as 
previously used in the work by Mirkin et al., are conjugated to 
the gold nanoparticles (Jin, R.; Wu, G.; Li, Z.; Mirkin, C. A.; Example 6 
A one-step highly sensitive method for DNA detection 
using dynamic light scattering. The inventors also demon-
strated that this invention can be used for DNA detection and 
analysis (Huo Q., et al. J. Am. Chem. Soc. 2008, 130, 8138-
8139). There is a considerable demand for rapid, low-cost, 
and sensitive detection of specific DNA sequences for the 
clinical diagnosis of genetic and pathogenic diseases. Cur-
rently fluorescent optical label-based DNA detection meth-
ods such as DNA microarray and molecular beacons are 
dominating the market. However, there are several limitations 
in these widely adopted methods. One problem is the rela-
tively low signal amplification. Because one DNA probe is 
labeled with one or a few fluorophores, the fluorescence sig-
nal is rather weak when the target DNA concentration is low, 
leading to relatively poor sensitivity. A second problem is the 
poor photostability of typical fluorophores. Most organic 
dyes suffer from serious photo bleaching and this often leads 
to irreproducible results. 
30 and Schatz, G. C.J.Am. Chem. Soc. 2003, 125, 1643. Stoeva, 
S. I.; Lee, J. S.; Thaxton, C. S.; and Mirkin, C. A. Angew. 
Chem. Int. Ed. 2006, 45, 3303). FIG. 17a is the UV-Vis 
absorption spectra of AuNPs probes before and after conju-
gating with DNA probes. The AuNP solution was initially 
35 pinkish-red with a SPR band at 520 nm. Upon functionaliza-
tion of single stranded DNA, the SPR band remained at 520 
nm, indicating no particle aggregation due to an increased 
repulsive interaction between nanoparticles after conjugating 
with single stranded DNAs. DLS measurement was used to 
40 monitor the size change of AuNPs before and after conjugat-
ing with the two DNA probes. As shown in FIG. 17b, the 
hydrodynamic diameter of the nanoparticles increased 
slightly from 29.0 nm to 34.4 nm for DNAl-AuNP and 38.2 
nm for DNA2-AuNP, respectively. This hydrodynamic diam-
45 eter change is caused by the addition of a DNA layer on the 
nanoparticle surface. The DLS data also revealed a very nar-
row size distribution of AuNPs before and after DNA modi-
fication. Both UV-Vis absorption and DLS measurement 
To solve some of these problems, several types of nanoma-
terials such as quantum dots, carbon nanotubes, silicon 50 
nanowires, and metallic nanoparticles have been explored as 
signaling probes for DNA detection. Among them, goldnano-
particles (AuNPs or GNPs) have been used in a variety of 
forms for detecting DNAs based on their unique size and 
distance-dependent optical properties. Mirkin and co-work- 55 
ers first developed a colorimetric detection of DNA hybrid-
ization in a homogeneous solution based on the formation of 
oligonucleotide-functionalized AuNPs aggregates in the 
presence of target DNAs (Elghanian, R.; Storhoff, J. J.; 
Mucic, R. C.; Letsinger, R. L.; Mirkin, C. A. Science 1997, 60 
277, 1078.) The nanoparticles aggregation can be detected 
directly by observing the color change of the solution from 
red to purple, or monitored by UV-Vis absorption spectros-
copy. However, the main limitation of this approach is its low 
sensitivity (10 nM). To increase the sensitivity, DNA bar code 65 
amplification and other optical signal amplification tech-
niques such as scanometric method, and surface enhanced 
indicate that the DNA-AuNP probes remained to be individu-
ally dispersed in the solution. 
For target DNA detection, a 1: 1 mixture solution of the two 
DNA-AuNP probes at a concentration of 100 µM was added 
to a set of target DNA solutions with a concentration ranging 
from 5 µM to 5 nM. The concentration ofDNA-AuNP probes 
was determined using UV-Vis absorption spectroscopy. The 
mixed solution was incubated for 5 min at 70° C., and then 
allowed to cool down to room temperature and set for 2 hours. 
The solution was then diluted 100 fold for DLS measurement 
(the DLS sample cell requires a 1-1.5 mL sample solution). 
As shown in FIG. l8a, the average size of gold nanoparticles 
in the control sample with 0 M target DNA in solution is 
around 35.2 nm. In a sample solution containing 5 µM target 
DNAs, the average nanoparticle size increased to 40.6 nm. 
The whole nanoparticle population now contains the indi-
vidually dispersed DNA-AuNP probes, nanoparticle dimers, 
trimers and oligomers formed due to hybridization between 
DNA targets and DNA probes. With increased concentration 
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of target DNAs, the average nanoparticle hydrodynamic 
diameter increased accordingly. FIG. 19 is a plot of the par-
ticle size over the target DNA concentration from 5 µM to 5 
nM. The detection limit is estimated to be around 1 µM. 
Without any optimization, this detection limit is already 4 
orders of magnitude higherthan absorption-basedmethods as 
reported previously (Elghanian, R.; Storhoff, J. J.; Mucic, R. 
C.; Letsinger, R. L.; Mirkin, C.A. Science 1997, 277, 1078). 
The assay exhibits excellent reproducibility, as judged from 
the small standard deviation of each concentration (three 10 
samples were run for each concentration) and a good linearity 
of the assay (see inset in FIG. 19). 
To examine the selectivity of the new assay, the inventors 
conducted a comparison study on single base pair-mis-
matched DNAs from perfectly matched DNA targets. Two 15 
types of mismatched DNA targets were studied: one with a 
mismatched pair located at the end and one with a mis-
matched pair in the middle of the target DNA sequence (mis-
matched sequences are shown in the Supporting Information 
ofthepaperbytheinventors, Huo Q., eta!. J.Am. Chem. Soc. 20 
2008, 130, 8138-8139). Under the exact same assay condi-
tions, DLS analysis revealed a much less degree of nanopar-
ticle aggregation when the target DNA has a single mis-
matched base pair, judging from the hydrodynamic diameter 
of the nanoparticles as shown in FIG. l8b. This single base 25 
pair mismatch study was conducted at a target DNA concen-
tration of 10 µM. The result demonstrates the capability of our 
new assay to discriminate single base pair-mismatched DNAs 
from perfectly matched target DNAs, without using the melt-
ing transition ofDNA-nanoparticle aggregates as required by 30 
a previously reported method (Elghanian, R.; Storhoff, J. J.; 
Mucic, R. C.; Letsinger, R. L.; Mirkin, C. A. Science 1997, 
277, 1078). 
In conclusion, the inventors demonstrated a one-step 
homogeneous hybridization assay for DNA detection based 35 
on the invention. This assay is extremely easy to conduct, 
provides much higher sensitivity compared to absorption-
based methods, however, without any signal amplification 
process. Single base pair-mismatched DNAs can be readily 
discriminated from perfectly complementary DNAs directly 40 
from the DLS analysis under ambient conditions. 
Example 7 
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angle should be selected to detect nanoparticle aggregates 
most sensitively. One example is a forward angle at 13 degree. 
Other angles may be used as well depending on the type of 
metal particles used and the assay formats. More than one 
detector may be used for simultaneous analysis of multiple 
samples. Outputs from detectors 211 and 212 are shown 
coupled to a correlator or other type of processor 221 associ-
ated with a computer 230 which using correlation software 
and is operable for determining the particle diffusion coeffi-
cients, and/or particle size and/or size distribution from the 
correlation function. The data collection, processing, analysis 
and display will be controlled by the computer 230. The 
computer software will convert the DLS data to analyte con-
centration information. A linear or non-linear relation exists 
between the DLS data of the assay solution and the analyte 
concentration. The absolute analyte concentration may be 
determined by comparison with a calibration curve obtained 
using standard analyte solutions with known concentrations. 
When standard analyte solutions are not available or it is not 
necessary to obtain the absolute concentration of the analyte, 
the nanoparticle diffusion coefficients, size and/ or size distri-
bution data may be used directly to obtain the relative analyte 
levels from different samples. 
In other more specific embodiments, the invention pertains 
to DLS systems that are particularly adapted to conduct assay 
embodiments of multiple samples simultaneously or sequen-
tially through automatic control. An example of such an 
adapted DLS system with two different setups is illustrated in 
FIG. 3. The first setup is used to analyze one sample solution 
at a time (FIG. 3c) and the second setup is used to measure 
multiple samples (means more than one sample) simulta-
neously (FIG. 3a and b ). Other than the required components 
for a basic DLS as shown in FIG. 2, this modified system 300 
contains the following additional features/components: (1) a 
laser beam 312 that can be split into multiple beams (or 
multiple lasers) as incident light beams 322 for multiple assay 
solutions 316, to thereby produce a scattered light signal 322; 
(2) a movable platform 318 such as carousel that can hold one 
or more than one assay solution containers. FIG. 3 illustrates 
an example of a carousel 318 that has 12 assay solution 
containers 316 or cell holders where cells that contain the 
assay solutions can be loaded to the holder manually or auto-
matically. The carousel 318 may be a stand-alone device. The 
carousel 318 will be inserted into the D LS main system manu-
DLS Systems 
FIG. 2 shows a basic DLS system 200 according to the 
invention for determining the presence of analytes in one 
sample at a time manually. System 200 comprises a vessel/ 
cell 204 formed from an optically transparent material for 
holding a sample solution suspected of containing at least one 
target analyte, and the same or two different nanoprobes 
conjugated with receptors. The receptors can be the same or 
different. A light source, such as laser 210 directs light with a 
suitable wavelength (e.g. ultraviolet, visible, near infrared, or 
infrared) at the analyte comprising solution which is con-
tained in a vessel/cell 204. An attenuator 217 may or may not 
be used to adjust the intensity of the incident laser beam from 
laser 210. At least one detector, such as detectors 211 and 212, 
is provided for measuring a scattered light signal from the 
analyte comprising solution. The detector may be placed at 
different angles in relative to the incident laser beam, from 0 
to 180 degree angle, in a more specific embodiment, 0-90 
degree. In one embodiment, the analyte detected excludes 
DNA, or if DNA is the target analyte, the detector relative to 
the laser must be between 0-90 degrees. At different detector 
angles, the sensitivity of the assay may vary. A best detector 
45 ally or automatically. The carousel may also rotate in-plane as 
illustrated in FIG. 3b (326). The system 300 may optionally 
include a liquid handling system 324 for delivering and/or 
removing fluid from the cells. 
Generally, the DLS is equipped with a single or multiple 
50 detectors. The number of detectors may match the number of 
sample solution containers in the carousel. The number of 
detectors may be smaller than the number of sample solution 
containers in the carousel. Each detector will detect the scat-
tered light signal from one sample solution. The data col-
55 lected from each detector may be processed by the same 
processor such as correlator sequentially or multiple proces-
sors simultaneously to obtain the correlation function of each 
assay solution. As an example, FIG. 3 illustrates that 12 
samples may be analyzed simultaneously using one laser 
60 source and 12 detectors. Alternatively, one can turn on only 
one detector, load one sample to the carousel a time. By 
rotating the carousel, the user can continuously load a new 
sample and unload the analyzed sample from the carousel so 
that multiple samples may be analyzed sequentially. FIG. 3 is 
65 only an illustration. Other settings that are based on the 
sample concept may be adapted as well. For example, the 
carousel may contain any number of sample solution contain-
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ers or cell holders other than 12. The carousel may be replaced 
by a microfluidic device with sample solution containers 
embedded in the device. The carousel may also be replaced by 
a device that does not have the circular shape as shown in FIG. 
3, but functions the same as a carousel. The different modes as 
discussed above (fixed carousel versus rotatable carousel 
using single or multiple detectors simultaneously) may be 
combined together to speed up the assay and reduce the cost. 
Shown in FIG. 3c is an alternative embodiment that pro-
vides for a reduction in the amount ofDLS detectors needed 10 
20 
specific examples (a non-exhaustive list) of the computer-
readable medium would include the following: an electrical 
connection having one or more wires, a portable computer 
diskette, a random access memory (RAM), a read-only 
memory (ROM), an erasable programmable read-only 
memory (EPROM or Flash memory), an optical fiber, and a 
portable compact disc read-only memory (CD-ROM), a CD 
ROM, a DVD (digital video disk), or other electronic storage 
medium. Note that the computer-usable or computer-read-
able medium could even be paper or another suitable medium 
upon which the program is printed, as the program can be 
electronically captured, via, for instance, optical scarming of 
the paper or other medium, then compiled, interpreted or 
but also allows the user the ability to manipulate samples in 
and out of the movable platform expediently. System 350 
includes a movable platform 355 that has at least a first 
container 354 and a second container 356. The movable plat-
form 355 may shift one or the other containers 354, 356 from 
a load zone 357 to a detection zone 359. The light source 351 
sends an incidental light beam 358 at the container in the 
detection zone 359 to thereby produce a scattered light signal 
360. The detector 361 detects the scattered light signal for 
further processing by a computer. 
15 otherwise processed in a suitable marmer if necessary, and 
then stored in a computer memory. 
Computer program code for carrying out operations of 
certain embodiments of the present invention may be written 
in an object oriented and/or conventional procedural pro-
For both DLS systems, a computer software will be used to 
control the liquid mixing, sample loading and unloading, and 
the DLS measurement; to process the scattering light inten-
sity data into correlation function; to process the correlation 
function data into particle diffusion coefficient, particle size 
and/or size distribution information; and to process such 
information into analyte concentration (including relative or 
absolute concentration) with and without the use of a calibra-
tion curve. Calibration curve is established by assaying a 
series of standard sample solution with known concentration 
of analytes. Typically, comparison ofDLS data obtained from 
an unknown sample solution with the calibration curve will 
reveal the analyte concentration in the unknown sample. 
20 gramming languages including, but not limited to, Java, 
Smalltalk, Peri, Python, Ruby, Lisp, PHP, "C", FORTRAN, 
or C++. The program code may execute entirely on the user's 
computer, partly on the user's computer, as a stand-alone 
software package, partly on the user's computer and partly on 
25 
a remote computer or entirely on the remote computer. In the 
latter scenario, the remote computer may be connected to the 
user's computer through a local area network (LAN) or a 
wide area network (WAN), or the connection may be made to 
30 an external computer (for example, through the Internet using 
an Internet Service Provider). 
It will be understood that functions of DLS systems 
described herein may be implemented by computer-readable 
program code modules. These program code modules may be As will be appreciated by one of skill in the art, embodi-
ments of the present invention may be embodied as a device 
or system comprising a processing module, and/or computer 
program product comprising at least one program code mod-
ule. Accordingly, the present invention may take the form of 
35 provided to a processing module of a general purpose com-
puter, special purpose computer, embedded processor or 
other programmable data processing apparatus to produce a 
machine, such that the program code modules, which execute 
via the processing module of the computer or other program-
40 mable data processing apparatus, create means for imple-
menting the functions specified in the flowchart and/or block 
diagram block or blocks. 
an entirely hardware embodiment or an embodiment combin-
ing software and hardware aspects. Furthermore, the present 
invention may include a computer program product on a 
computer-usable storage medium having computer-usable 
program code means embodied in the medium. Any suitable 
computer readable medium may be utilized including hard 
disks, CD-ROMs, DVDs, optical storage devices, or mag- 45 
netic storage devices. 
The term "processing module" may include a single pro-
cessing device or a plurality of processing devices. Such a 
processing device may be a microprocessor, micro-control-
ler, digital signal processor, microcomputer, central process- 50 
ing unit, field programmable gate array, programmable logic 
device, state machine, logic circuitry, analog circuitry, digital 
circuitry, and/or any device that manipulates signals (analog 
and/or digital) based on operational instructions. The pro-
cessing module may have operationally coupled thereto, or 55 
integrated therewith, a memory device. The memory device 
may be a single memory device or a plurality of memory 
devices. Such a memory device may be a read-only memory, 
random access memory, volatile memory, non-volatile 
memory, static memory, dynamic memory, flash memory, 60 
and/or any device that stores digital information. A computer, 
as used herein, is a device that comprises at least one process-
ing module, and optionally at least one memory device. 
The computer-usable or computer-readable medium may 
be or include, for example, but not limited to, an electronic, 65 
magnetic, optical, electromagnetic, infrared, or semiconduc-
tor system, apparatus, device, or propagation medium. More 
These computer program code modules may also be stored 
in a computer-readable memory that can direct a computer or 
other progranimable data processing apparatus to function in 
a particular manner, such that the program code modules 
stored in the computer-readable memory produce an article of 
manufacture. 
The computer program code modules may also be loaded 
onto a computer or other programmable data processing 
apparatus to cause a series of operational steps to be per-
formed on the computer or other progranimable apparatus to 
produce a computer implemented process such that the 
instructions which execute on the computer or other program-
mable apparatus provide steps for implementing the func-
tions specified in the flowchart and/or block diagram block or 
blocks. 
This invention can be embodied in other forms without 
departing from the spirit or essential attributes thereof and, 
accordingly, reference should be to the following claims 
rather than the foregoing specification as indicating the scope 
of the invention. 
The disclosure of all references cited are incorporated in 
their entirety to the extent not inconsistent with the teachings 
herein. 
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<160> NUMBER OF SEQ ID NOS, 3 
<210> SEQ ID NO 1 
<211> LENGTH, 12 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
22 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
probe 
<400> SEQUENCE, 1 
taacaatccc tc 
<210> SEQ ID NO 2 
<211> LENGTH, 15 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
12 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
probe 
<400> SEQUENCE, 2 
atccttatca atatt 
<210> SEQ ID NO 3 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
15 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
gagggattat tgttaaatat tgataaggat 
What is claimed is: 
1. A dynamic light scattering (DLS) apparatus for assaying 
multiple sample solutions simultaneously, said system com- 40 
prising: 
a computer; 
a carousel housing comprising a plurality of containers for 
holding a plurality of sample solutions 
a light source interior to the carousel that delivers inciden- 45 
ta! light to a side of each container of said plurality of 
containers simultaneously to produce scattered light that 
exits out of the side of each container; 
a display; 
a plurality of detectors each arranged so as to sense light 50 
scattering of said multiple samples, wherein said scat-
tered light that exits out of the side of each container is 
detected simultaneously, wherein the plurality of detec-
30 
tors are placed to detect the scattered light at a scattering 
angle between zero and ninety degrees; 
a first program code module for directing said computer to 
initiate lighting said multiple samples; 
a second program code module for measuring light scat-
tering from said cell and processing light scattering sig-
nal into DLS data; 
a third program code module for directing said computer to 
process DLS data of individual samples into relative or 
absolute analyte concentration information; and 
a fourth program code module for directing said computer 
to display said information on a display device, wherein 
said DLS data is obtained from two or more samples of 
said multiple samples simultaneously. 
* * * * * 
